Safety of Monoclonal Antibodies Inhibiting PCSK9 in Pregnancy: Disproportionality Analysis in VigiBase®

Documenti analoghi

• BCR::ABL1 Tyrosine Kinase Inhibitors During Pregnancy, a Disproportionality Analysis of Vigibase
  di: Aurélie Cabannes‐Hamy, et al.
  Pubblicazione: (2025)
• Janus Kinase Inhibitors During Pregnancy and Adverse Drug Reactions: A Pharmacovigilance Disproportionality Analysis in V igi B ase
  di: Nazanin Abolhassani, et al.
  Pubblicazione: (2025)
• Subcutaneous Administration of Monoclonal Antibodies: Pharmacology, Delivery, Immunogenicity, and Learnings From Applications to Clinical Development
  di: John D. Davis, et al.
  Pubblicazione: (2024)
• Pharmacokinetics of the Monoclonal Antibody, Sotrovimab, in Healthy Participants Following IM Administration at Different Injection Sites
  di: Asma El‐Zailik, et al.
  Pubblicazione: (2024)
• JAK Inhibitors and Memory Impairment: Disproportionality Analyses in the WHO Global Pharmacovigilance Database, VigiBase
  di: Marilou Duboëlle, et al.
  Pubblicazione: (2026)